Kate Haviland - Mar 1, 2025 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role
CHIEF EXECUTIVE OFFICER
Signature
/s/ Melissa Masse, Attorney-in-Fact
Stock symbol
BPMC
Transactions as of
Mar 1, 2025
Transactions value $
$0
Form type
4
Date filed
3/4/2025, 05:19 PM
Previous filing
Jan 23, 2025
Next filing
Mar 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Award $0 +35.2K +23.56% $0.00 185K Mar 1, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Award $0 +70.4K $0.00 70.4K Mar 1, 2025 Common Stock 70.4K $96.57 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involved the Reporting Person's receipt of a grant of 35,200 restricted stock units under the Issuer's 2024 Stock Incentive Plan.
F2 This option vests with respect to 1/48th of the shares underlying the option on April 1, 2025 and as to an additional 1/48th of the shares underlying the option each month thereafter.